1. Personalizing Management in the Care of Patients With Advanced Sarcoma

3. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Challenges in Treating Soft Tissue Sarcomas

5. Case 1: 67-Year-Old Hispanic Man

6. Case 1: Diagnostic Workup

7. Case 1: Initial Treatment

8. Case 1: Follow-Up

9. Selected Therapeutic Options

10. Case 1: Second-Line Therapy

11. Trabectedin and Eribulin

12. PFS Benefit in Leiomyosarcoma and Liposarcoma

13. Other Current and Emerging Second-Line and Later Options

14. Concluding Remarks: Liposarcomas

15. Case 2: 56-Year-Old Woman With Pelvic Discomfort

16. Case 2: Treatment Considerations

17. Selected Initial Regimens for Leiomyosarcoma

18. Phase 1b/2 Trial of Olaratumab Plus Doxorubicin in Soft Tissue Sarcoma

19. GeDDiS: Randomized Phase 3 Trial of Gemcitabine Plus Docetaxel vs Doxorubicin

20. Case 2: Symptom Control

21. Concluding Remarks: Leiomyosarcoma

22. Abbreviations

23. Abbreviations (cont)